Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × neratinib × Clear all

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03812393 2023-12-18

FACT-2

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms